Objectives: The objectives of this study were to observe the Efficacy of unani pharmacopoeial formulation Boozidan (Pyrethrum indicum) for the management of Niqris Muzmin (Chronic gout) and to observe any concomitant and adverse effects of formulation. Methods: This single blind, randomized and standard control clinical study was conducted between April 2021 to October 2021 for a period of 28 days. 60 patients diagnosed with chronic gout were divided into two groups, 30 Test group and 30 Control group. The test group was administered with 5g boozidaan in powder form once daily with water and the patients of control group were given tablet febuxostat 80mg once daily. Patients were followed up and improvements in subjective parameters were assessed weekly at 7th, 14th, 21st, and 29th day. Objective parameters were assessed at the baseline and at 29th day. The data obtained was subjected to statistical analysis. Results: Both the test and control drug were effective in reducing Serum uric acid level, ESR and CRP levels. A significant improvement in subjective and objective parameters was observed in both test and control groups and no adverse effects were observed during and after the study. However, the test drug had superior efficacy in reducing the objective parameters and it was statistically significant (p-value<0.0001). Conclusion: Both Boozidaan and Febuxostat were safe and significantly effective in resolving the symptoms and signs of gouty arthritis and both have significant effect on reducing serum uric acid level. Keywords: Boozidaan, Chronic gout, Niqris, Febuxostat, serum uric acid, unani medicine
Background: Unani System of medicine provides an alternative source to relieve the symptoms of Rheumatoid Arthritis, to slow the progression of disease, and to tackle the disadvantages associated with conventional drugs. Habb-e-Asgand is an important Unani pharmacopeial formulation which is commonly prescribed for Rheumatoid Arthritis. Hence, current study is designed to investigate its efficacy and safety in the management of Waja‘ al-Mafāṣil (Rheumatoid Arthritis).Methods: This parallel group, randomized, single blind clinical trial compared unani formulation Habb-e-Asgand 2pills (each of 650mg) at bed time orally, with Sulfasalazine 500 mg tablets twice a day orally as control. The total number of patients completing the trial was 20 in each group and treatment was given for 45 days. For evaluating subjective parameters, patients were asked to follow up every 15 days during the trial and objective parameters were assessed on the 0th and 46th days of the trial.Results: There was statistically significant difference between Test and Control treatment with respect to subjective parameters, joint pain (p-value˂0.0001*), morning stiffness (pvalue˂0.0001*), joints swelling (p-value˂0.0001*), joints tenderness (p-value˂0.0001*), restricted movement of the joints (p-value˂0.002*) which means that the treatments in the test group were more effective in resolving them. The objective parameter such as HAQ-DI, DAS-28, RA factor and soft tissue swelling on x-ray show statistically significant reduction in test group in comparison to the control group with p-value.Conclusion: These finding suggested that Habb-e-Asgand is safely and effectively used in the management of Waja‘ al-Mafāṣil (Rheumatoid Arthritis).Trial registration: CTRI no.- CTRI/2022/01/039602.
21 December 2019 in Journal of Complementary and Integrative Medicine
Background: Vitiligo, a skin disorder is viewed as a multifactorial process with major role of reactive oxygen species in concert to destroy or incapacitate melanocytes. In Unani system of medicine the treatment of Bars (Vitiligo) starts with removal of harmful materials from the body with Munzij and Mushil (MM), a poly herbal Unani formulation. Methods: Herein, oxidative stress related parameters as MDA, SOD, GPx and CAT have been estimated in the 21 clinically diagnosed Vitiligo in-patients and subsequently these parameters were evaluated during and after administration of MM therapy and compared with 21 healthy subjects. Results: There was significant difference in the parameters viz., SOD (p<0.001) and CAT (p<0.005) activity at the baseline with no statistical significant difference in MDA and GPx activity among Vitiligo subjects and controls. After MM therapy there was no statistical significant difference among the values of these parameters in Vitiligo subjects. Conclusions: The results suggest that there is imbalance in the oxidant-antioxidant status of Vitiligo subjects and the MM therapy is not found to significantly change the levels of oxidative stress related parameters.
30 December 2021 in Journal of Ayurvedic and Herbal Medicine